Published in Onco Targets Ther on September 07, 2010
Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer. J Surg Res (2011) 1.54
Molecular determinants of retinoic acid sensitivity in pancreatic cancer. Clin Cancer Res (2011) 0.97
Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther (2013) 0.95
Radiofrequency ablation for unresectable locally advanced pancreatic cancer: a systematic review. HPB (Oxford) (2013) 0.89
In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens. Mol Cancer (2012) 0.85
Cytokine-induced killer cell therapy for advanced pancreatic adenocarcinoma: A case report and review of the literature. Oncol Lett (2013) 0.84
Review of endoscopic radiofrequency in biliopancreatic tumours with emphasis on clinical benefits, controversies and safety. World J Gastroenterol (2016) 0.81
A prospective study of patient reported outcomes in pancreatic and peri-ampullary malignancy. World J Surg (2013) 0.80
Antimetabolite Treatment for Pancreatic Cancer. Chemotherapy (Los Angel) (2014) 0.79
Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. Cell Death Dis (2015) 0.79
Personalized virotherapy in cancer. Aging (Albany NY) (2015) 0.78
Microencapsulated tumor assay: evaluation of the nude mouse model of pancreatic cancer. World J Gastroenterol (2012) 0.78
Cell death in response to antimetabolites directed at ribonucleotide reductase and thymidylate synthase. Onco Targets Ther (2015) 0.78
Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study. Support Care Cancer (2016) 0.76
Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. Cell Death Discov (2015) 0.76
Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63. Oncotarget (2016) 0.75
Irreversible Electroporation of the Pancreas Using Parallel Plate Electrodes in a Porcine Model: A Feasibility Study. PLoS One (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA (2007) 14.54
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg (1985) 7.14
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol (2005) 5.82
Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res (2008) 5.21
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol (2009) 5.11
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol (2006) 4.70
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol (2003) 4.56
Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol (2006) 4.50
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol (2004) 4.37
Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA (2001) 4.30
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol (2002) 4.15
Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA (2009) 3.86
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol (2004) 3.56
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol (2005) 3.28
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer (2008) 3.19
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol (2004) 3.10
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol (2005) 2.88
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res (2002) 2.70
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol (2009) 2.66
Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy. Ann Surg (1999) 2.65
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer (2006) 2.57
Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg (1999) 2.57
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer (2002) 2.53
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol (2006) 2.51
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol (2001) 2.39
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol (2007) 2.33
Risk of pancreatic cancer in families with Lynch syndrome. JAMA (2009) 2.32
Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg (1993) 2.26
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res (2003) 2.23
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol (2005) 2.18
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol (2008) 2.15
Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study. Eur J Cancer (1993) 2.14
Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol (2009) 2.11
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol (2006) 2.10
Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol (2001) 2.01
Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol Ther (2008) 1.89
Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol (2005) 1.88
Do preoperative biliary stents increase postpancreaticoduodenectomy complications? J Gastrointest Surg (2000) 1.86
A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer (2009) 1.84
Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg (1995) 1.79
Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. Ann Surg Oncol (1999) 1.73
Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist (2008) 1.70
Celiac plexus block: a reappraisal. Reg Anesth Pain Med (1998) 1.70
Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer (1993) 1.69
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys (2002) 1.69
FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer (2000) 1.68
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res (2009) 1.62
Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol (2002) 1.56
Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev (2006) 1.56
Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J (1980) 1.55
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res (1990) 1.50
Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother (2005) 1.47
Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol (2006) 1.45
The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. Population-based study. Am J Gastroenterol (2007) 1.43
Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol (2002) 1.39
Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev (2008) 1.38
BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol (2008) 1.36
National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Ann Surg (1996) 1.35
Symptom relief and quality of life after stenting for malignant bile duct obstruction. Gut (1994) 1.34
Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg (2004) 1.34
Genetic and epigenetic alterations of familial pancreatic cancers. Cancer Epidemiol Biomarkers Prev (2008) 1.31
Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? J Gastrointest Surg (2002) 1.31
Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer (2009) 1.25
Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg (2000) 1.20
Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg (1993) 1.19
Adjuvant therapy for pancreatic cancer--the debate continues. N Engl J Med (2004) 1.18
Preoperative irradiation in carcinoma of the pancreas. Cancer (1980) 1.18
On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg (2006) 1.17
Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg (2003) 1.16
A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer (1990) 1.12
Obesity, pancreatitis, and pancreatic cancer. Obes Surg (2008) 1.10
Chemotherapy for pancreatic cancer. N Engl J Med (2004) 1.09
Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci (2009) 1.08
Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development. J Clin Oncol (2009) 1.08
Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother (2002) 1.08
Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg (2004) 1.08
Risk factors for cholecystitis after metal stent placement in malignant biliary obstruction. Gastrointest Endosc (2006) 1.06
Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg (2008) 1.03
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol (2005) 1.02
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs (2010) 1.01
Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. JOP (2006) 1.00
Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol (2009) 0.99
The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia. J Support Oncol (2008) 0.99
Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. Am J Clin Oncol (2003) 0.97
Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer. Zhonghua Zhong Liu Za Zhi (2002) 0.96
Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen. Cancer Res (2003) 0.95
Guidelines for the surgical management of pancreatic adenocarcinoma. Semin Oncol (2007) 0.94